Nyxoah SA (NYXH) News
Filter NYXH News Items
NYXH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NYXH News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest NYXH News From Around the Web
Below are the latest news stories about NYXOAH SA that investors may wish to consider to help them evaluate NYXH as an investment opportunity.
Publication relating to transparency notificationsREGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 20, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On December 19, 2024, Nyxoah received a transparency notification from BlackRock, Inc. and related persons. Based on the |
Nyxoah introduces neurostimulator device for sleep apnoea in EnglandThe battery-free, single-incision, and leadless system represents a solution for adults suffering from moderate to severe OSA. |
Tongue Implant Could Treat Sleep Apnea Without a CPAPIt uses neurostimulation to keep the tongue from sliding back and blocking the airway. |
Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in EnglandNyxoah Announces Commercial Launch of Genio® Innovative Therapy in EnglandFirst patients implanted with Genio at UCLH, London Mont-Saint-Guibert, Belgium – December 13, 2024, 8:05am CET / 2:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the commercial launch of its Genio system in England, marked by the first |
Information on the total number of voting rights and sharesREGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), November 27, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6,429,682.56 Total number of securities carrying voting rights: 37,427,265 (all ordinary shares) Total number o |
Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference Mont-Saint-Guibert, Belgium – November 20, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will participate in the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. T |
Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024REGULATED INFORMATIONNovember 19, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024 The board of directors of the Company is pleased to invite its securities holders to attend the special shareholders' meeting of the Company, to be held on Thursday, December 19, 2024 at 3:00 p.m. CET at the Com |
Nyxoah SA (NYXH) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesNyxoah SA (NYXH) strengthens its financial position and prepares for US market entry despite increased operating losses and delayed FDA approval. |
Nyxoah SA (NYXH) Reports Q3 Loss, Tops Revenue EstimatesNyxoah (NYXH) delivered earnings and revenue surprises of -47.83% and 17.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Nyxoah Reports Third Quarter Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports Third Quarter Financial and Operating ResultsFDA approval on track for first quarter 2025, U.S. commercial team build out in progressCompany fully funded with cash until mid 2026 Mont-Saint-Guibert, Belgium – November 6, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, |